Members /

Shionogi Inc.

Since its founding in 1878, Shionogi has been dedicated to developing innovative treatments to improve the lives of patients worldwide. The company focuses on addressing global health challenges, including antimicrobial resistance and COVID-19, through a commitment to scientific excellence and strategic partnerships.

Shionogi Inc. Logo

Shionogi Inc.

What We Do

FETROJA®

(cefiderocol) for injection, an antibiotic for treating infections due to Gram-negative bacteria.

MULPLETA®

(lusutrombopag) tablets, for oral use, used to treat thrombocytopenia.

METHYLIN®

(methylphenidate HCl) oral solution, CII, used for the treatment of ADHD.

Infectious Diseases

Viral
Bacterial

Drugs

Small Molecule Drugs

Services

Clinical Research Organizations (CRO)
Preclinical Development

Routes of Administration

Intravenous
Oral

Regenerative Medicine

Bone

Biologics

Gene Therapy
Cellular Therapy

Key People

Nathan McCutcheon

President and Chief Executive Officer

LinkedIn

David Benadon

Senior Vice President, Chief Human Resources Officer

LinkedIn

Margaret Borys

Executive Vice President and Chief Commercial Officer

LinkedIn

Masahiro Fujita

Senior Vice President and Chief Financial Officer

LinkedIn

Tadashi Hara

Executive Vice President and Chief Global Operations Officer

LinkedIn

Chris Klein

Senior Vice President and General Counsel

LinkedIn